The Accelerated Approval Program for Oncology Drugs: Celebrating More Than 250,000 Life-Years Gained and Counting
This commentary explores how 2 recently published studies evaluating the clinical benefit of the FDA’s accelerated approval program for oncology drugs came to different conclusions.
Prescription Rebate Guarantees: Employer Insights
This study examined employers’ understanding of rebate guarantees, dependency upon rebate dollars, and the role that pharmaceutical rebates or employer benefits consultants play in their pharmacy benefits manager selection.
Unintended Consequences of the Inflation Reduction Act: Clinical Development Toward Subsequent Indications
The Inflation Reduction Act will likely change incentives surrounding single-indication launches and postapproval research for additional indications in small molecule drugs, affecting patient access.
Good Health Policy Requires High-Quality Evidence. Let’s Remember That With Drug Pricing.
In the health spending debate, what policy makers need most is an honest, realistic, and evidence-based discussion. Unfortunately, many studies in the public arena fall far short.
